➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Colorcon
Boehringer Ingelheim
Moodys
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Onyx Therapeutics, Inc. v. CIPLA Limited
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Onyx Therapeutics, Inc. v. CIPLA Limited
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Onyx Therapeutics, Inc. v. CIPLA Limited (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-10-24 1 Complaint 16. United States Patent No. 7,232,818 (the “’818 Patent”), entitled “Compounds For Enzyme Inhibition…Product prior to the expiration of U.S. Patent Nos. 7,417,042; 7,232,818; 7,491,704; 7,737,112; 8,129,346;… COUNT II: INFRINGEMENT OF U.S. PATENT NO. 7,232,818 53. Plaintiff hereby realleges… THE PATENTS-IN-SUIT 15. United States Patent No. 7,417,042 (the “’042 Patent”), entitled… This is a civil action for patent infringement under the patent laws of the United States, Title External link to document
2018-04-17 203 Redacted Document Relevant Onyx’s U.S. Patent No. 7,737,112 (“Onyx’s formulation patent”) contains claims directed…by claims of the Patents-in-Suit. In this litigation, Onyx is asserting five patents, which are directed…alternative formulations to the patented formulations or to “design around” the Patents-in-Suit (Topics 3-5 of …own patents on formulations of carfilzomib. These defendants are effectively arguing to the Patent Office…. (“Onyx”) in the above-referenced matter. This patent infringement action, arising under the Hatch-Waxman External link to document
2018-06-26 240 Notice of Service Opening Expert Report on Invalidity of U.S. Patent Nos. 7,417,042; 7,737,112; 8,207,125; 8,207,126 and 8,207,127… 2016 15 May 2020 1:16-cv-00988 830 Patent None District Court, D. Delaware External link to document
2018-08-09 247 Notice of Service Amiji, Ph.D., R.Ph on Invalidity of U.S. Patent Nos. 7,417,042; 7,737,112; 8,207,125; 8,207,126 and 8,207,127… 2016 15 May 2020 1:16-cv-00988 830 Patent None District Court, D. Delaware External link to document
2018-10-10 273 Notice of Service Amiji, Ph.D., R.Ph on Invalidity of U.S. Patent Nos. 7,417,042; 7,737,112; and 8,207,125 filed by InnoPharma… 2016 15 May 2020 1:16-cv-00988 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
Johnson and Johnson
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.